Rabbit Anti-GJC2 Recombinant Antibody (EG875) (CBMAB-EN1045-LY)

Go to compare Compare Online Inquiry
Request for COA
Datasheet Target Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal
Rabbit
Clone
EG875
Application
WB: 1:500~1:1000 IF: 1:100~1:500 ELISA: 1:5000
Immunogen
The antibody was produced against synthesized peptide derived from internal of human CXG2.
Specificity
Human, Mouse, Rat
Antibody Isotype
IgG
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.
More Infomation

Target

Full Name
Gap Junction Protein Gamma 2
Entrez Gene ID
Human57165
Mouse118454
Rat497913
UniProt ID
HumanQ5T442
MouseQ8BQU6
RatQ80XF7
Function
One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. May play a role in myelination in central and peripheral nervous systems.
Biological Process
Brain development Source: Ensembl
Cell-cell signaling Source: GO_Central
Cell communication by electrical coupling Source: UniProtKB
Negative regulation of G1/S transition of mitotic cell cycle Source: Ensembl
Positive regulation of calcium ion transmembrane transport Source: Ensembl
Positive regulation of gene expression Source: Ensembl
Positive regulation of oligodendrocyte progenitor proliferation Source: Ensembl
Regulation of protein phosphorylation Source: Ensembl
Response to toxic substance Source: Ensembl
Cellular Location
Cell membrane; Gap junction
Involvement in disease
Leukodystrophy, hypomyelinating, 2 (HLD2):
An autosomal recessive hypomyelinating leukodystrophy with symptoms of Pelizaeus-Merzbacher disease. Clinically characterized by nystagmus, impaired motor development, ataxia, choreoathetotic movements, dysarthria, and progressive spasticity.
Spastic paraplegia 44, autosomal recessive (SPG44):
A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.
Lymphatic malformation 3 (LMPHM3):
A form of primary lymphedema, a disease characterized by swelling of body parts due to developmental anomalies and functional defects of the lymphatic system. Patients with lymphedema may suffer from recurrent local infections. LMPHM3 is an autosomal dominant form with variable severity and reduced penetrance. Affected individuals manifest lymphedema of the lower limbs and some patients have lymphedema of the hands.
Topology
Cytoplasmic: 1-25
Helical: 26-46
Extracellular: 47-78
Helical: 79-99
Cytoplasmic: 100-216
Helical: 217-237
Extracellular: 238-265
Helical: 266-286
Cytoplasmic: 287-439
Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Rabbit Anti-GJC2 Recombinant Antibody (EG875)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

online inquiry
Online Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.